16 results on '"Rogozinski, Sophia"'
Search Results
2. The comorbidity and co-medication profile of patients with progressive supranuclear palsy
- Author
-
Greten, Stephan, Wegner, Florian, Jensen, Ida, Krey, Lea, Rogozinski, Sophia, Fehring, Meret, Heine, Johanne, Doll-Lee, Johanna, Pötter-Nerger, Monika, Zeitzschel, Molly, Hagena, Keno, Pedrosa, David J., Eggers, Carsten, Bürk, Katrin, Trenkwalder, Claudia, Claus, Inga, Warnecke, Tobias, Süß, Patrick, Winkler, Jürgen, Gruber, Doreen, Gandor, Florin, Berg, Daniela, Paschen, Steffen, Classen, Joseph, Pinkhardt, Elmar H., Kassubek, Jan, Jost, Wolfgang H., Tönges, Lars, Kühn, Andrea A., Schwarz, Johannes, Peters, Oliver, Dashti, Eman, Priller, Josef, Spruth, Eike J., Krause, Patricia, Spottke, Annika, Schneider, Anja, Beyle, Aline, Kimmich, Okka, Donix, Markus, Haussmann, Robert, Brandt, Moritz, Dinter, Elisabeth, Wiltfang, Jens, Schott, Björn H., Zerr, Inga, Bähr, Mathias, Buerger, Katharina, Janowitz, Daniel, Perneczky, Robert, Rauchmann, Boris-Stephan, Weidinger, Endy, Levin, Johannes, Katzdobler, Sabrina, Düzel, Emrah, Glanz, Wenzel, Teipel, Stefan, Kilimann, Ingo, Prudlo, Johannes, Gasser, Thomas, Brockmann, Kathrin, Hoffmann, Daniel C., Klockgether, Thomas, Krause, Olaf, Heck, Johannes, Höglinger, Günter U., and Klietz, Martin
- Published
- 2024
- Full Text
- View/download PDF
3. Clinical presentation of posterior cerebral artery occlusions – Clinical rationale for a more aggressive therapeutic strategy?
- Author
-
Maus, Volker, Rogozinski, Sophia, Borggrefe, Jan, Barnikol, Utako Birgit, Saklak, Muharrem, and Mpotsaris, Anastasios
- Published
- 2021
- Full Text
- View/download PDF
4. The comorbidity and co-medication profile of patients with progressive supranuclear palsy
- Author
-
Greten, Stephan, primary, Wegner, Florian, additional, Jensen, Ida, additional, Krey, Lea, additional, Rogozinski, Sophia, additional, Fehring, Meret, additional, Heine, Johanne, additional, Doll-Lee, Johanna, additional, Pötter-Nerger, Monika, additional, Zeitzschel, Molly, additional, Hagena, Keno, additional, Pedrosa, David J., additional, Eggers, Carsten, additional, Bürk, Katrin, additional, Trenkwalder, Claudia, additional, Claus, Inga, additional, Warnecke, Tobias, additional, Süß, Patrick, additional, Winkler, Jürgen, additional, Gruber, Doreen, additional, Gandor, Florin, additional, Berg, Daniela, additional, Paschen, Steffen, additional, Classen, Joseph, additional, Pinkhardt, Elmar H., additional, Kassubek, Jan, additional, Jost, Wolfgang H., additional, Tönges, Lars, additional, Kühn, Andrea A., additional, Schwarz, Johannes, additional, Peters, Oliver, additional, Dashti, Eman, additional, Priller, Josef, additional, Spruth, Eike J., additional, Krause, Patricia, additional, Spottke, Annika, additional, Schneider, Anja, additional, Beyle, Aline, additional, Kimmich, Okka, additional, Donix, Markus, additional, Haussmann, Robert, additional, Brandt, Moritz, additional, Dinter, Elisabeth, additional, Wiltfang, Jens, additional, Schott, Björn H., additional, Zerr, Inga, additional, Bähr, Mathias, additional, Buerger, Katharina, additional, Janowitz, Daniel, additional, Perneczky, Robert, additional, Rauchmann, Boris-Stephan, additional, Weidinger, Endy, additional, Levin, Johannes, additional, Katzdobler, Sabrina, additional, Düzel, Emrah, additional, Glanz, Wenzel, additional, Teipel, Stefan, additional, Kilimann, Ingo, additional, Prudlo, Johannes, additional, Gasser, Thomas, additional, Brockmann, Kathrin, additional, Hoffmann, Daniel C., additional, Klockgether, Thomas, additional, Krause, Olaf, additional, Heck, Johannes, additional, Höglinger, Günter U., additional, and Klietz, Martin, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Automatic covariance pattern analysis outperforms visual reading of 18F‐fluorodeoxyglucose‐positron emission tomography (FDG‐PET) in variant progressive supranuclear palsy.
- Author
-
Buchert, Ralph, Wegner, Florian, Huppertz, Hans‐Jürgen, Berding, Georg, Brendel, Matthias, Apostolova, Ivayla, Buhmann, Carsten, Dierks, Alexander, Katzdobler, Sabrina, Klietz, Martin, Levin, Johannes, Mahmoudi, Nima, Rinscheid, Andreas, Rogozinski, Sophia, Rumpf, Jost‐Julian, Schneider, Christine, Stöcklein, Sophia, Spetsieris, Phoebe G., Eidelberg, David, and Wattjes, Mike P.
- Abstract
Background: To date, studies on positron emission tomography (PET) with 18F‐fluorodeoxyglucose (FDG) in progressive supranuclear palsy (PSP) usually included PSP cohorts overrepresenting patients with Richardson's syndrome (PSP‐RS). Objectives: To evaluate FDG‐PET in a patient sample representing the broad phenotypic PSP spectrum typically encountered in routine clinical practice. Methods: This retrospective, multicenter study included 41 PSP patients, 21 (51%) with RS and 20 (49%) with non‐RS variants of PSP (vPSP), and 46 age‐matched healthy controls. Two state‐of‐the art methods for the interpretation of FDG‐PET were compared: visual analysis supported by voxel‐based statistical testing (five readers) and automatic covariance pattern analysis using a predefined PSP‐related pattern. Results: Sensitivity and specificity of the majority visual read for the detection of PSP in the whole cohort were 74% and 72%, respectively. The percentage of false‐negative cases was 10% in the PSP‐RS subsample and 43% in the vPSP subsample. Automatic covariance pattern analysis provided sensitivity and specificity of 93% and 83% in the whole cohort. The percentage of false‐negative cases was 0% in the PSP‐RS subsample and 15% in the vPSP subsample. Conclusions: Visual interpretation of FDG‐PET supported by voxel‐based testing provides good accuracy for the detection of PSP‐RS, but only fair sensitivity for vPSP. Automatic covariance pattern analysis outperforms visual interpretation in the detection of PSP‐RS, provides clinically useful sensitivity for vPSP, and reduces the rate of false‐positive findings. Thus, pattern expression analysis is clinically useful to complement visual reading and voxel‐based testing of FDG‐PET in suspected PSP. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Brain MRI in Progressive Supranuclear Palsy with Richardson's Syndrome and Variant Phenotypes.
- Author
-
Wattjes, Mike P., Huppertz, Hans‐Jürgen, Mahmoudi, Nima, Stöcklein, Sophia, Rogozinski, Sophia, Wegner, Florian, Klietz, Martin, Apostolova, Ivayla, Levin, Johannes, Katzdobler, Sabrina, Buhmann, Carsten, Quattrone, Andrea, Berding, Georg, Brendel, Matthias, Barthel, Henryk, Sabri, Osama, Höglinger, Günter, and Buchert, Ralph
- Abstract
Background: Brain magnetic resonance imaging (MRI) is used to support the diagnosis of progressive supranuclear palsy (PSP). However, the value of visual descriptive, manual planimetric, automatic volumetric MRI markers and fully automatic categorization is unclear, particularly regarding PSP predominance types other than Richardson's syndrome (RS). Objectives: To compare different visual reading strategies and automatic classification of T1‐weighted MRI for detection of PSP in a typical clinical cohort including PSP‐RS and (non‐RS) variant PSP (vPSP) patients. Methods: Forty‐one patients (21 RS, 20 vPSP) and 46 healthy controls were included. Three readers using three strategies performed MRI analysis: exclusively visual reading using descriptive signs (hummingbird, morning‐glory, Mickey‐Mouse), visual reading supported by manual planimetry measures, and visual reading supported by automatic volumetry. Fully automatic classification was performed using a pre‐trained support vector machine (SVM) on the results of atlas‐based volumetry. Results: All tested methods achieved higher specificity than sensitivity. Limited sensitivity was driven to large extent by false negative vPSP cases. Support by automatic volumetry resulted in the highest accuracy (75.1% ± 3.5%) among the visual strategies, but performed not better than the midbrain area (75.9%), the best single planimetric measure. Automatic classification by SVM clearly outperformed all other methods (accuracy, 87.4%), representing the only method to provide clinically useful sensitivity also in vPSP (70.0%). Conclusions: Fully automatic classification of volumetric MRI measures using machine learning methods outperforms visual MRI analysis without and with planimetry or volumetry support, particularly regarding diagnosis of vPSP, suggesting the use in settings with a broad phenotypic PSP spectrum. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson's Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy
- Author
-
Rogozinski, Sophia, Klietz, Martin, Respondek, Gesine, Oertel, Wolfgang H, Grothe, Michel J, Pereira, Joana B, Höglinger, Günter U, Instituto de Salud Carlos III, and European Commission
- Subjects
Aging ,Cognitive Neuroscience ,Progressive supranuclear palsy ,multiple system atrophy ,progressive supranuclear palsy ,Multiple system atrophy ,Voxel-based morphometry ,cholinergic innervation ,nucleus basalis of Meynert ,Subcortical dementia ,subcortical dementia ,Nucleus basalis of Meynert ,Parkinson’s disease ,voxel-based morphometry ,Cholinergic innervation ,ddc:610 - Abstract
[Objectives] To study in vivo gray matter (GM) volumes of the nucleus basalis of Meynert (nbM) in different parkinsonian syndromes and assess their relationship with clinical variables., [Methods] T1-weighted magnetic resonance images from patients with progressive supranuclear palsy (PSP, N = 43), multiple system atrophy (MSA, N = 23), Parkinson’s disease (PD, N = 26), and healthy controls (HC, N = 29) were included. T1-weighted images were analyzed using a voxel-based morphometry approach implemented in the VBM8 toolbox, and nbM volumes were extracted from the spatially normalized GM images using a cyto-architectonically-defined nbM mask in stereotactic standard space. NbM volumes were compared between groups, while controlling for intracranial volume. Further, within each group correlation analyses between nbM volumes and the Mini Mental Status Examination (MMSE), Hoehn and Yahr stage, PSP Rating Scale, Unified Parkinson’s Disease Rating Scale part III and Frontal Assessment Battery scores were performed., [Results] Significantly lower nbM volumes in patients with PSP and PD compared to HC or patients with MSA were found. No significant correlations between MMSE and nbM volumes were detected in any of the subgroups. No significant correlations were found between clinical scores and nbM volumes in PSP or other groups., [Conclusion] nbM volumes were reduced both in PD and PSP but not in MSA. The lack of significant correlations between nbM and cognitive measures suggests that other factors, such as frontal atrophy, may play a more important role than subcortical cholinergic atrophy in PSP patients. These results may indicate that other drug-targets are needed to improve cognitive function in PSP patients., MG was supported by the “Miguel Servet” program (CP19/00031) and a research grant (PI20/00613) of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER).
- Published
- 2022
8. Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson's Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy
- Author
-
Instituto de Salud Carlos III, European Commission, Rogozinski, Sophia, Klietz, Martin, Respondek, Gesine, Oertel, Wolfgang H., Grothe, Michel J., Pereira, Joana B., Höglinger, Günter U., Instituto de Salud Carlos III, European Commission, Rogozinski, Sophia, Klietz, Martin, Respondek, Gesine, Oertel, Wolfgang H., Grothe, Michel J., Pereira, Joana B., and Höglinger, Günter U.
- Abstract
[Objectives] To study in vivo gray matter (GM) volumes of the nucleus basalis of Meynert (nbM) in different parkinsonian syndromes and assess their relationship with clinical variables., [Methods] T1-weighted magnetic resonance images from patients with progressive supranuclear palsy (PSP, N = 43), multiple system atrophy (MSA, N = 23), Parkinson’s disease (PD, N = 26), and healthy controls (HC, N = 29) were included. T1-weighted images were analyzed using a voxel-based morphometry approach implemented in the VBM8 toolbox, and nbM volumes were extracted from the spatially normalized GM images using a cyto-architectonically-defined nbM mask in stereotactic standard space. NbM volumes were compared between groups, while controlling for intracranial volume. Further, within each group correlation analyses between nbM volumes and the Mini Mental Status Examination (MMSE), Hoehn and Yahr stage, PSP Rating Scale, Unified Parkinson’s Disease Rating Scale part III and Frontal Assessment Battery scores were performed., [Results] Significantly lower nbM volumes in patients with PSP and PD compared to HC or patients with MSA were found. No significant correlations between MMSE and nbM volumes were detected in any of the subgroups. No significant correlations were found between clinical scores and nbM volumes in PSP or other groups., [Conclusion] nbM volumes were reduced both in PD and PSP but not in MSA. The lack of significant correlations between nbM and cognitive measures suggests that other factors, such as frontal atrophy, may play a more important role than subcortical cholinergic atrophy in PSP patients. These results may indicate that other drug-targets are needed to improve cognitive function in PSP patients.
- Published
- 2022
9. Reduction in Volume of Nucleus Basalis of Meynert Is Specific to Parkinson’s Disease and Progressive Supranuclear Palsy but Not to Multiple System Atrophy
- Author
-
Rogozinski, Sophia, primary, Klietz, Martin, additional, Respondek, Gesine, additional, Oertel, Wolfgang H., additional, Grothe, Michel J., additional, Pereira, Joana B., additional, and Höglinger, Günter U., additional
- Published
- 2022
- Full Text
- View/download PDF
10. Neuropsychiatric Symptoms in Parkinson’s Disease Patients Are Associated with Reduced Health-Related Quality of Life and Increased Caregiver Burden
- Author
-
Eichel, Hannah von, primary, Heine, Johanne, additional, Wegner, Florian, additional, Rogozinski, Sophia, additional, Stiel, Stephanie, additional, Groh, Adrian, additional, Krey, Lea, additional, Höglinger, Günter U., additional, and Klietz, Martin, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Klinik, Verlauf und Therapieentscheidungen bei Infarkten im Stromgebiet der A. cerebri posterior aus neuroradiologischer Sicht
- Author
-
Mpotsaris, Anastasios, Burghaus, Lothar, Rogozinski, Sophia Marie, and Universit��tsklinikum K��ln. Institut F��r Diagnostische Und Interventionelle Radiologie
- Subjects
Medizin und Gesundheit - Published
- 2021
- Full Text
- View/download PDF
12. Postinfektiöse Myasthenia gravis bei einer COVID-19-Patientin
- Author
-
Huber, Meret, primary, Rogozinski, Sophia, additional, Puppe, Wolfram, additional, Framme, Carsten, additional, Höglinger, Günter, additional, Hufendiek, Karsten, additional, and Wegner, Florian, additional
- Published
- 2021
- Full Text
- View/download PDF
13. Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient
- Author
-
Huber, Meret, primary, Rogozinski, Sophia, additional, Puppe, Wolfram, additional, Framme, Carsten, additional, Höglinger, Günter, additional, Hufendiek, Karsten, additional, and Wegner, Florian, additional
- Published
- 2020
- Full Text
- View/download PDF
14. SEND-PD in Parkinsonian Syndromes: Results of a Monocentric Cross-Sectional Study.
- Author
-
Veith Sanches L, Greten S, Doll-Lee J, Rogozinski SM, Heine J, Krey L, Ulaganathan S, Jensen I, Höllerhage M, Sani SS, Höglinger GU, Wegner F, and Klietz M
- Abstract
Introduction: Neuropsychiatric symptoms in particular impair health-related quality of life (QoL) of patients with Parkinson's disease and atypical Parkinsonian syndromes. For this reason, various scales have been developed for detection of neuropsychiatric symptoms, such as the Scale for evaluation of neuropsychiatric disorders in Parkinson's disease (SEND-PD)., Objective: First, the objective of this study was to explore the interrelation between the SEND-PD and clinical parameters in patients with Parkinson's disease and thus confirm its validity. In addition, the applicability in a well-defined cohort of patients with atypical Parkinsonian syndromes was investigated for the very first time., Methods: A clinically well-defined cohort of 122 patients with Parkinson's disease (PD), 55 patients with Progressive Supranuclear Palsy (PSP) and 33 patients with Multiple System Atrophy (MSA) were analyzed. First, the SEND-PD was correlated with established disease-specific scores in patients with PD. Next, the results of the SEND-PD were compared between the different Parkinsonian syndromes., Results: The SEND-PD showed a strong significant correlation with several scores, especially the UPDRS I (Rho = 0.655) and GDS-15 (Rho = 0.645). Depressive burden was significantly higher in MSA patients in comparison to the PD patient cohort (PD, 3.8 ± 3.3; MSA, 5.45 ± 3.87), while PSP patients showed significantly less psychotic (PD 1.6 ± 2.1; PSP 0.6 ± 0.9) and impulse control disorders (PD 0.3 ± 1.0; PSP 0.02 ± 0.1)., Conclusion: The SEND-PD is a useful, brief and highly applicable screening tool for neuropsychiatric symptoms in PD, but not in atypical Parkinsonism, as their unique neuropsychiatric symptom composition is not fully captured., Competing Interests: All authors declare that there is no conflict of interest., (© 2024 Veith Sanches et al.)
- Published
- 2024
- Full Text
- View/download PDF
15. Added value of FDG-PET for detection of progressive supranuclear palsy.
- Author
-
Buchert R, Huppertz HJ, Wegner F, Berding G, Brendel M, Apostolova I, Buhmann C, Poetter-Nerger M, Dierks A, Katzdobler S, Klietz M, Levin J, Mahmoudi N, Rinscheid A, Quattrone A, Rogozinski S, Rumpf JJ, Schneider C, Stoecklein S, Spetsieris PG, Eidelberg D, Sabri O, Barthel H, Wattjes MP, and Höglinger G
- Abstract
Background: Diagnostic criteria for progressive supranuclear palsy (PSP) include midbrain atrophy in MRI and hypometabolism in [
18 F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) as supportive features. Due to limited data regarding their relative and sequential value, there is no recommendation for an algorithm to combine both modalities to increase diagnostic accuracy. This study evaluated the added value of sequential imaging using state-of-the-art methods to analyse the images regarding PSP features., Methods: The retrospective study included 41 PSP patients, 21 with Richardson's syndrome (PSP-RS), 20 with variant PSP phenotypes (vPSP) and 46 sex- and age-matched healthy controls. A pretrained support vector machine (SVM) for the classification of atrophy profiles from automatic MRI volumetry was used to analyse T1w-MRI (output: MRI-SVM-PSP score). Covariance pattern analysis was applied to compute the expression of a predefined PSP-related pattern in FDG-PET (output: PET-PSPRP expression score)., Results: The area under the receiver operating characteristic curve for the detection of PSP did not differ between MRI-SVM-PSP and PET-PSPRP expression score (p≥0.63): about 0.90, 0.95 and 0.85 for detection of all PSP, PSP-RS and vPSP. The MRI-SVM-PSP score achieved about 13% higher specificity and about 15% lower sensitivity than the PET-PSPRP expression score. Decision tree models selected the MRI-SVM-PSP score for the first branching and the PET-PSPRP expression score for a second split of the subgroup with normal MRI-SVM-PSP score, both in the whole sample and when restricted to PSP-RS or vPSP., Conclusions: FDG-PET provides added value for PSP-suspected patients with normal/inconclusive T1w-MRI, regardless of PSP phenotype and the methods to analyse the images for PSP-typical features., Competing Interests: Competing interests: H-JH has used atlas-based volumetric MRI analysis in industry-sponsored research projects. CB received a grant from the Hilde-Ulrichs-Stiftung, served as a consultant for Bial, Hormosan Pharma, Merz Pharmaceuticals and Zambon and received honoraria for scientific presentations from Abbvie, Bial, Stada Pharma, TAD Pharma, UCB Pharma and Zambon. MP-N received lecture fees from Abbott, Abbvie, Boston Scientific and served as consultant for Medtronic, Boston Scientific, Abbott, Zambon and Abbvie. SK was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy–ID 390857198), the Ehrmann Foundation and the Lüneburg Heritage. SK receives research funding from CurePSP and reports travel support from Life Molecular Imaging outside the submitted work. MK received honoraria for scientific presentations from Abbvie and Ever Pharma. JL reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA and Roche, consulting fees from Axon Neuroscience and Biogen, author fees from Thieme medical publishers and W. Kohlhammer medical publishers and is inventor in a patent 'Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies' (EP 23 156 122.6) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG, is beneficiary of the phantom share program of MODAG and is inventor in a patent 'Pharmaceutical Composition and Methods of Use' (EP 22 159 408.8) filed by MODAG, all activities outside the submitted work. J-JR received speaker honoraria from GE Healthcare. OS received research support from Life Molecular Imaging. HB received reader honoraria from Life Molecular Imaging and speaker honoraria from Novartis/AAA. MPW received speaker or consultancy honoraria from Alexion, Bayer Healthcare, Biogen, Biologix, Bristol Myers Squibb, Celgene, Genilac, Imcyse, IXICO, Icometrix, Medison, Merck-Serono, Novartis, Roche, Sanofi-Genzyme. Publication royalties from Springer and Elsevier. GH was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy–ID 390857198) and within the Hannover Cluster RESIST (EXC 2155–project number 39087428), the EU/EFPIA/Innovative Medicines Initiative (2) Joint Undertaking (IMPRIND grant no 116060), the European Joint Programme on Rare Diseases (Improve-PSP), Deutsche Forschungsgemeinschaft (DFG, HO2402/6-2 Heisenberg Program, HO2402/18-1 MSAomics), the VolkswagenStiftung (Niedersächsisches Vorab), the Petermax-Müller Foundation (Etiology and Therapy of Synucleinopathies and Tauopathies); participated in indurtry-sponsored research projects from Abbvie, Biogen, Biohaven, Novartis, Roche, Sanofi, UCB; served as a consultant for Abbvie, Alzprotect, Aprineua, Asceneuron, Bial, Biogen, Biohaven, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, UCB; received honoraria for scientific presentations from Abbvie, Bayer Vital, Bial, Biogen, Bristol Myers Squibb, Kyowa Kirin, Roche, Teva, UCB, Zambon; received publication royalties from Academic Press, Kohlhammer and Thieme. All other authors declare that they have no potential conflicts of interest., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2024
- Full Text
- View/download PDF
16. Automatic covariance pattern analysis outperforms visual reading of 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in variant progressive supranuclear palsy.
- Author
-
Buchert R, Wegner F, Huppertz HJ, Berding G, Brendel M, Apostolova I, Buhmann C, Dierks A, Katzdobler S, Klietz M, Levin J, Mahmoudi N, Rinscheid A, Rogozinski S, Rumpf JJ, Schneider C, Stöcklein S, Spetsieris PG, Eidelberg D, Wattjes MP, Sabri O, Barthel H, and Höglinger G
- Subjects
- Humans, Fluorodeoxyglucose F18, Positron-Emission Tomography methods, Retrospective Studies, Movement Disorders, Supranuclear Palsy, Progressive diagnosis
- Abstract
Background: To date, studies on positron emission tomography (PET) with
18 F-fluorodeoxyglucose (FDG) in progressive supranuclear palsy (PSP) usually included PSP cohorts overrepresenting patients with Richardson's syndrome (PSP-RS)., Objectives: To evaluate FDG-PET in a patient sample representing the broad phenotypic PSP spectrum typically encountered in routine clinical practice., Methods: This retrospective, multicenter study included 41 PSP patients, 21 (51%) with RS and 20 (49%) with non-RS variants of PSP (vPSP), and 46 age-matched healthy controls. Two state-of-the art methods for the interpretation of FDG-PET were compared: visual analysis supported by voxel-based statistical testing (five readers) and automatic covariance pattern analysis using a predefined PSP-related pattern., Results: Sensitivity and specificity of the majority visual read for the detection of PSP in the whole cohort were 74% and 72%, respectively. The percentage of false-negative cases was 10% in the PSP-RS subsample and 43% in the vPSP subsample. Automatic covariance pattern analysis provided sensitivity and specificity of 93% and 83% in the whole cohort. The percentage of false-negative cases was 0% in the PSP-RS subsample and 15% in the vPSP subsample., Conclusions: Visual interpretation of FDG-PET supported by voxel-based testing provides good accuracy for the detection of PSP-RS, but only fair sensitivity for vPSP. Automatic covariance pattern analysis outperforms visual interpretation in the detection of PSP-RS, provides clinically useful sensitivity for vPSP, and reduces the rate of false-positive findings. Thus, pattern expression analysis is clinically useful to complement visual reading and voxel-based testing of FDG-PET in suspected PSP. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society., (© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.)- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.